- Home
- MYND vs ADIL Comparison
MYND vs ADIL Comparison
Compare MYND & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MYND | ADIL |
|---|---|---|
| Founded | 1998 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2M | 18.5M |
| IPO Year | 2017 | 2017 |
Fundamental Metrics
Financial Performance| Metric | MYND | ADIL |
|---|---|---|
| Price | $0.38 | $4.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $37.50 |
| AVG Volume (30 Days) | 43.1K | ★ 63.4K |
| Earning Date | 05-27-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $0.13 |
| 52 Week High | $1.15 | $7.20 |
Technical Indicators
Market Signals| Indicator | MYND | ADIL |
|---|---|---|
| Relative Strength Index (RSI) | 44.57 | 58.97 |
| Support Level | $0.30 | $1.63 |
| Resistance Level | $0.44 | $6.41 |
| Average True Range (ATR) | 0.05 | 0.68 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 11.38 | 58.94 |
Price Performance
Historical ComparisonAbout MYND Mynd.ai Inc.
Mynd.ai Inc provides world'wide, end-to-end, learning solutions and collaboration tools to help teachers, schools, students, and professionals realize their greatest potential. The company has single reporting segment. The company has presence in United States and Rest of world. The company generates majority of revenue from United States.
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.